What Happened?
New York, NY-based C2i Genomics Appointed Lilach Fridman-Gabai as Director, Operations and Finance
About the Company
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
About the Person
Lilach Fridman-Gabai is Director, Operations and Finance at C2i Genomics. Previously, Lilach held various senior HR leadership roles in the industry.
Info Source
News
Short Profile